LONDON: Shares in GSK, Sanofi and Haleon fell sharply on Thursday, following declines earlier this week, amid growing investor concerns about U.S. litigation focused on a heartburn drug that contained a probable carcinogen. GSK shares were down just over 10%, Sanofi's stock had sagged about 3.3% and Haleon's shares had slipped nearly 5% at the close of trading on Thursday. GSK and Sanofi at various points sold the drug - originally branded as Zantac - which U.S. regulators ordered off the market in 2020.

https://www.brecorder.com/news/40191111

#brecorder